Fuchs Endothelial Corneal Dystrophy: Clinical, Genetic, Pathophysiologic, and Therapeutic Aspects.


Journal

Annual review of vision science
ISSN: 2374-4650
Titre abrégé: Annu Rev Vis Sci
Pays: United States
ID NLM: 101660822

Informations de publication

Date de publication:
15 09 2019
Historique:
entrez: 17 9 2019
pubmed: 17 9 2019
medline: 10 5 2020
Statut: ppublish

Résumé

Fuchs endothelial corneal dystrophy (FECD) is a bilateral corneal endothelial disorder and the most common cause of corneal transplantation worldwide. Professor Ernst Fuchs described the first 13 cases of FECD more than 100 years ago. Since then, we have seen far-reaching progress in its diagnosis and treatment. In the field of diagnostics, new technologies enable the development of more accurate classification systems and the more detailed breakdown of the genetic basis of FECD. Laboratory studies help in deciphering the molecular pathomechanisms. The development of minimally invasive surgical techniques leads to a continuous improvement of the postoperative result. This review highlights and discusses clinical, genetic, pathophysiologic, and therapeutic aspects of this common and important corneal disorder.

Identifiants

pubmed: 31525145
doi: 10.1146/annurev-vision-091718-014852
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

151-175

Auteurs

Mario Matthaei (M)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; email: mario.matthaei@uk-koeln.de, agathe.hribek@uk-koeln.de, thomas.clahsen@uk-koeln.de, bjoern.bachmann@uk-koeln.de, claus.cursiefen@uk-koeln.de.

Agathe Hribek (A)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; email: mario.matthaei@uk-koeln.de, agathe.hribek@uk-koeln.de, thomas.clahsen@uk-koeln.de, bjoern.bachmann@uk-koeln.de, claus.cursiefen@uk-koeln.de.

Thomas Clahsen (T)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; email: mario.matthaei@uk-koeln.de, agathe.hribek@uk-koeln.de, thomas.clahsen@uk-koeln.de, bjoern.bachmann@uk-koeln.de, claus.cursiefen@uk-koeln.de.

Björn Bachmann (B)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; email: mario.matthaei@uk-koeln.de, agathe.hribek@uk-koeln.de, thomas.clahsen@uk-koeln.de, bjoern.bachmann@uk-koeln.de, claus.cursiefen@uk-koeln.de.

Claus Cursiefen (C)

Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, 50937 Cologne, Germany; email: mario.matthaei@uk-koeln.de, agathe.hribek@uk-koeln.de, thomas.clahsen@uk-koeln.de, bjoern.bachmann@uk-koeln.de, claus.cursiefen@uk-koeln.de.

Albert S Jun (AS)

Wilmer Eye Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA; email: aljun@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH